Inogen (INGN) Loses 10.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Inogen (INGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
INGN looks poised as Q3 revenue rises 4%, POC demand grows and valuation is low, despite seasonal softness.
INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite
Inogen launches Aurora CPAP masks to expand its respiratory care suite and enter the growing sleep apnea market.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.
Down 19.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Inogen (INGN)
Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Slow Progress At Inogen
Inogen (INGN) continues its turnaround, showing progress in revenue growth and margins, but the pace remains slower and riskier than the market desires. INGN posted positive adjusted EBITDA and raised full-year guidance, despite mixed quarterly results and ongoing volatility in direct-to-consumer and rental segments. The company's strong market position, new product launches, and partnerships offer long-term growth potential, especially as patients consistently prefer portable solutions.
Inogen Stock Dips Despite Q3 Earnings Beat, Revenues Up Y/Y
INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.
Inogen, Inc. (INGN) Q3 2025 Earnings Call Transcript
Inogen, Inc. ( INGN ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Lorna Williams Kevin Smith - President, CEO & Director Michael Bourque - Executive VP, CFO & Corporate Treasurer Conference Call Participants Joseph Conway - Needham & Company, LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Presentation Operator Welcome to Inogen's Third Quarter 2025 Earnings Conference Call.
Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.25 per share a year ago.
Why Fast-paced Mover Inogen (INGN) Is a Great Choice for Value Investors
Inogen (INGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
